Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Astellas Submits Supplemental New Drug Application In Japan For PADCEV™ With KEYTRUDA® For First-Line Treatment Of Advanced Bladder Cancer

Author: Benzinga Newsdesk | January 31, 2024 02:34am

– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy –

– If approved, PADCEV with KEYTRUDA would be the first combination in Japan to offer an alternative to chemotherapy, the current standard of care in first-line locally advanced or metastatic urothelial cancer –

Posted In: ALPMY MRK